




Searching News Database: rituximab
HSMN NewsFeed - 31 Jan 2025
U.S. FDA Approves Celltrion's AVTOZMA(R) (tocilizumab-anoh), a Biosimilar to ACTEMRA(R)
U.S. FDA Approves Celltrion's AVTOZMA(R) (tocilizumab-anoh), a Biosimilar to ACTEMRA(R)
HSMN NewsFeed - 30 Apr 2024
Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer (CBO)
Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer (CBO)
HSMN NewsFeed - 15 Jun 2018
MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress
MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress
HSMN NewsFeed - 23 May 2018
mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States
mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States
HSMN NewsFeed - 3 Nov 2016
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
HSMN NewsFeed - 13 Nov 2015
AbbVie Submits IMBRUVICA(R) (ibrutinib) Phase III Combination Data to U.S. FDA
AbbVie Submits IMBRUVICA(R) (ibrutinib) Phase III Combination Data to U.S. FDA
HSMN NewsFeed - 6 Jan 2014
PIXUVRI(R) (pixantrone) Receives Positive Final Appraisal Determination from NICE
PIXUVRI(R) (pixantrone) Receives Positive Final Appraisal Determination from NICE
HSMN NewsFeed - 4 Dec 2013
Cell Therapeutics and GKV-SV Reach Agreement on Pricing of PIXUVRI(R) (pixantrone) in Germany
Cell Therapeutics and GKV-SV Reach Agreement on Pricing of PIXUVRI(R) (pixantrone) in Germany
HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
HSMN NewsFeed - 15 Oct 2013
Second Draft NICE Guidance for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Second Draft NICE Guidance for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
HSMN NewsFeed - 19 Aug 2013
Market Access Granted in France for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Market Access Granted in France for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
HSMN NewsFeed - 8 Jul 2013
Market Access Granted in Italy for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Market Access Granted in Italy for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
HSMN NewsFeed - 14 Mar 2013
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
HSMN NewsFeed - 21 Feb 2013
ARIAD Announces Appointment of European General Manager and Other Key Members of Leadership Team
ARIAD Announces Appointment of European General Manager and Other Key Members of Leadership Team
HSMN NewsFeed - 31 May 2012
Cell Therapeutics' Pixuvri(R) Phase 3 Clinical Trial Results Published in The Lancet Oncology
Cell Therapeutics' Pixuvri(R) Phase 3 Clinical Trial Results Published in The Lancet Oncology
HSMN NewsFeed - 16 May 2012
Epizyme Announces Appointment of Eric Hedrick, M.D., as Chief Medical Officer
Epizyme Announces Appointment of Eric Hedrick, M.D., as Chief Medical Officer
HSMN NewsFeed - 19 Mar 2012
Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCL
Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCL
HSMN NewsFeed - 18 Oct 2011
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
HSMN NewsFeed - 19 Apr 2011
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
HSMN NewsFeed - 22 Mar 2011
FDA Accepts for Review Spectrum Pharmaceuticals’ ZEVALIN(R) Submission for the Removal of the Bioscan
FDA Accepts for Review Spectrum Pharmaceuticals’ ZEVALIN(R) Submission for the Removal of the Bioscan
HSMN NewsFeed - 24 May 2010
Seattle Genetics Names Vice President, Sales and Announces Management Promotion
Seattle Genetics Names Vice President, Sales and Announces Management Promotion
HSMN NewsFeed - 19 Mar 2010
Levact(R) (bendamustine) Recommended for Approval in Europe for Treating Blood Cancers
Levact(R) (bendamustine) Recommended for Approval in Europe for Treating Blood Cancers
HSMN NewsFeed - 3 Nov 2009
ZEVALIN(R) Receives Positive Reimbursement Ruling Using Average Sales Price (ASP) Methodology
ZEVALIN(R) Receives Positive Reimbursement Ruling Using Average Sales Price (ASP) Methodology
HSMN NewsFeed - 31 Jul 2009
Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
HSMN NewsFeed - 19 Jun 2009
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
HSMN NewsFeed - 11 Mar 2009
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
HSMN NewsFeed - 29 Jan 2009
Immunomedics Reports Properties and Structure-Function Relationships of Veltuzumab
Immunomedics Reports Properties and Structure-Function Relationships of Veltuzumab
HSMN NewsFeed - 10 Dec 2008
MorphoSys Appoints Dr. Arndt Schottelius as Chief Development Officer and Member of the Management Board
MorphoSys Appoints Dr. Arndt Schottelius as Chief Development Officer and Member of the Management Board
HSMN NewsFeed - 15 May 2008
Human Genome Sciences Names Kevin P. McRaith Vice President, Hepatology Franchise
Human Genome Sciences Names Kevin P. McRaith Vice President, Hepatology Franchise
HSMN NewsFeed - 20 Mar 2008
Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
HSMN NewsFeed - 20 Feb 2008
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
HSMN NewsFeed - 19 Feb 2008
FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma
FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma
HSMN NewsFeed - 21 Sep 2007
Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
HSMN NewsFeed - 29 Aug 2007
FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
HSMN NewsFeed - 3 Jun 2007
Genentech Provides Update on Pipeline Agents at the American Society of Clinical Oncology Meeting
Genentech Provides Update on Pipeline Agents at the American Society of Clinical Oncology Meeting
HSMN NewsFeed - 15 May 2007
Point Therapeutics Announces Interim Analysis to be Performed on Its Phase 3 Talabostat with Alimta Study
Point Therapeutics Announces Interim Analysis to be Performed on Its Phase 3 Talabostat with Alimta Study
HSMN NewsFeed - 7 May 2007
Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
HSMN NewsFeed - 30 Apr 2007
Dr Reddy's launches Reditux(TM) - Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma
Dr Reddy's launches Reditux(TM) - Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma
HSMN NewsFeed - 12 Apr 2007
GSK Initiates REPEAT Dosing Study of Its Novel Oral Platelet Growth Factor, PROMACTA(R), in ITP
GSK Initiates REPEAT Dosing Study of Its Novel Oral Platelet Growth Factor, PROMACTA(R), in ITP
HSMN NewsFeed - 7 Feb 2007
Biogen Idec Initiates Randomized, Registrational Trial of Lumiliximab for Chronic Lymphocytic Leukemia
Biogen Idec Initiates Randomized, Registrational Trial of Lumiliximab for Chronic Lymphocytic Leukemia
HSMN NewsFeed - 25 Jan 2007
Biogen Idec Initiates Phase III Trial of Galiximab for Follicular Non-Hodgkin's Lymphoma
Biogen Idec Initiates Phase III Trial of Galiximab for Follicular Non-Hodgkin's Lymphoma
HSMN NewsFeed - 24 Jan 2007
Point Therapeutics Announces Resignation of William Whelan from Board of Directors
Point Therapeutics Announces Resignation of William Whelan from Board of Directors
HSMN NewsFeed - 12 Jan 2007
Point Therapeutics Provides Preliminary Results from Phase 2 Metastatic Pancreatic Cancer Study
Point Therapeutics Provides Preliminary Results from Phase 2 Metastatic Pancreatic Cancer Study
HSMN NewsFeed - 12 Dec 2006
Cell Therapeutics, Inc. (CTI) Announces Pixantrone Combination Regimen Produces High Response Rates
Cell Therapeutics, Inc. (CTI) Announces Pixantrone Combination Regimen Produces High Response Rates
HSMN NewsFeed - 11 Dec 2006
VELCADE(R) (Bortezomib) for Injection Demonstrates Substantial Activity Across Range of Lymphomas
VELCADE(R) (Bortezomib) for Injection Demonstrates Substantial Activity Across Range of Lymphomas
HSMN NewsFeed - 8 Dec 2006
FDA Approves VELCADE(R) (Bortezomib) for Injection for Aggressive Form of Non-Hodgkin's Lymphoma
FDA Approves VELCADE(R) (Bortezomib) for Injection for Aggressive Form of Non-Hodgkin's Lymphoma
HSMN NewsFeed - 8 Dec 2006
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
HSMN NewsFeed - 16 Nov 2006
FDA Approves Herceptin(R) for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
FDA Approves Herceptin(R) for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
HSMN NewsFeed - 31 Oct 2006
Berlex Oncology Evaluating Combination Therapy for Common Form of Non-Hodgkin's Lymphoma
Berlex Oncology Evaluating Combination Therapy for Common Form of Non-Hodgkin's Lymphoma
HSMN NewsFeed - 29 Sep 2006
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
HSMN NewsFeed - 27 Jun 2006
Phase III Study of Avastin(R) in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
Phase III Study of Avastin(R) in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
HSMN NewsFeed - 23 May 2006
Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
HSMN NewsFeed - 11 May 2006
Genentech Announces Vice President Appointments in Commercial Operations and Product Development
Genentech Announces Vice President Appointments in Commercial Operations and Product Development
HSMN NewsFeed - 10 May 2006
Immunomedics and UCB Announce Worldwide Development Collaboration and License Agreement for Epratuzumab
Immunomedics and UCB Announce Worldwide Development Collaboration and License Agreement for Epratuzumab
Additional items found! 176

Members Archive contains
176 additional stories matching:
rituximab
(Password required)
rituximab
(Password required)